Login to Your Account



Other News To Note


Wednesday, February 22, 2012
• Cellartis AB, of Gothenburg, Sweden, a division of Cellectis SA, said it will participate in the €2 billion (US$2.69 billion) Innovative Medicines Initiative (IMI), a public-private European initiative to speed the development of new therapeutics. The IMI is supporting collaborative research projects, including an initial effort to develop a preclinical liver test system that surpasses the predictive power of the drug-induced liver injury (DILI) test.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription